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Aim: To investigate whether the early administration of Euphrasia eye drops® in preterm
neonates presenting with ocular discharge fosters the resolution of the ocular discharge
and reduces the need for topical antibiotic therapy, as compared to placebo.
Methods: We conducted a randomized double-blind placebo-controlled trial at the
University Children’s Hospital Bern, Switzerland. Preterm neonates with white, yellow,
or green ocular discharge were included. Infants were randomly assigned (1:1) to the
Euphrasia arm (Euphrasia eye drops®, Weleda AG, Arlesheim) or the placebo arm (NaCl
0.9%). Euphrasia or placebo was administrated at a dose of one drop in each eye four
times a day over a period of 96 h. The primary outcome was the treatment success,
defined as no ocular discharge at 96 h and no use of topical antibiotic therapy during the
96-h intervention.
Results: A total of 114 neonates were screened and 84 were randomized. Among
neonates in the Euphrasia arm, 22 (55.0%) achieved our primary outcome compared
to 21 (51.2%) in the placebo arm (p = 0.85). In the Euphrasia arm, time to resolution
of reddening tended to fall within the shorter bracket of 24 to 48 h (24 (92.3%) vs. 12
(80.0%) in the placebo arm, p = 0.34) and relapse or first signs of reddening during the
96-h intervention tended to be lower [3 (7.9%) eyes vs. 8 (18.2%) eyes in the placebo
arm, p = 0.17]. Tearing at 96 h tended to be lower in the Euphrasia arm [5 (12.8%) eyes
in the Euphrasia arm vs. 12 (27.3%) eyes in the placebo arm, p = 0.10].
Discussion: Euphrasia did not significantly improve treatment success, defined as
no ocular discharge at 96 h and no use of topical antibiotic therapy during the 96-h
intervention. However, results suggest that Euphrasia may be of benefit for symptoms
such as reddening and tearing, and thus improve the comfort of patients.
Trial Registration: The trial is registered at the US National Institutes of
Health (ClinicalTrials.gov) NCT04122300 and at the portal for human research in
Switzerland SNCTP000003490.
Keywords: ocular discharge, congenital nasolacrimal duct obstruction, preterm neonate, Euphrasia drops,
complementary medicine
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INTRODUCTION
Neonatal ocular discharge is mostly related to ophthalmia
neonatorum (neonatal conjunctivitis) or to congenital
nasolacrimal duct obstruction (CNLDO).
Ophthalmia neonatorum is a relatively common illness,
defined as conjunctivitis occurring within the first month
of life (1). Ophthalmia neonatorum can be caused by the
sexually transmitted pathogens of Neisseria gonorrhoeae and
Chlamydia trachomatis, by bacteria such as Staphylococcus
species, Streptococcus species, Haemophilus species and other
gram-negative bacterial species, or much less commonly by viral
infections (herpes simplex and adenovirus virus). The organisms
inducing ophthalmia neonatorum are usually acquired during
the birth process, from the mother’s birth canal, or after
birth from the immediate surroundings (2–4). Epidemiology
of organisms that induce ophtalmia neonatorum substantially
differs between developing countries and developed countries
(3). In the United States Neisseria gonorrhoeae counts for <1%
of cases and C. trachomatis for 2–40% of cases, while 30–50% of
cases are caused by other bacteria (1).
Ophthalmia neonatorum must be distinguished from ocular
discharge related to CNLDO. CNLDO occurs in ∼10–20% of
all term newborns, and is the most common cause of persistent
tearing and ocular discharge in children. It results from a
congenital abnormality of the lacrimal drainage system in the
form of a membranous obstruction of the nasolacrimal duct
of one or both eyes (5). Spontaneous resolution, through the
spontaneous perforation of themembrane, occurs by 6months of
age in ∼90% of infants (5). The first clinical signs appear during
the first month of life in 95% of cases (5) and usually consist of
tearing and debris on the eyelashes (“mattering”). Mucopurulent
eye discharge occurs commonly in infants with CNLDO and,
in the absence of other signs of infection, suggests bacterial
overgrowth in the stagnant tear pool of the lacrimal sac (“chronic
dacryocystitis”) (6).
In most instances, ocular discharge is a mild illness.
Complication such as microbial keratitis and acute dacryocystitis
are rare but can be serious, resulting in severe visual impairment
(e.g., corneal diseases), or blindness (7–9). In consequence,
topical antibiotic therapy is recommended in case of significant
mucopurulent discharge in order to control the bacterial
overgrowth, to avoid further inflammatory damage, and to
prevent serious infective complications (4, 6, 10, 11). This
therapy should be started just after bacterial/viral and chlamydial
swabs have been taken. However, the use of antibiotics as
the first-line treatment in infants who present with ocular
discharge has be questioned in light of other possible treatment
strategies (conservative management). At the time of the study
it was generally recommended to apply NaCl 0.9% locally in
neonates presenting with a white or yellow ocular discharge,
and to introduce a topical antibiotic therapy should symptoms
become stronger.
A previous pilot study suggested that early treatment with
Euphrasia eye drops in 24 neonates with ocular discharge with
or without tearing and reddened eye might reduce the antibiotic
consumption (12). Euphrasia (eyebright) eye drops (from
Euphrasia officinalis) are a frequently prescribed medication for
the treatment of irritative, infectious, or allergic conjunctivitis
and other affections of the eye (13–15). It is also effective
against hyperemia. It has been used for more than 70 years for
the structuring of the fluid organism in the eye, especially in
inflammatory and catarrhal conjunctivitis (13). Euphrasia has
an anti-inflammatory effect through the aucubin (inhibition of
prostaglandin synthesis), as well as an antibacterial effect through
phenolic carboxylic acids and flavonoids. Previous studies have
reported excellent tolerance of Euphrasia eye drops in adults and
children (12, 13, 15).
The present study—a randomized double-blind placebo-
controlled trial—follows our previous pilot study (12) and aimed
to investigate whether early administration of Euphrasia eye
drops (Weleda AG, Arlesheim) in preterm neonates presenting
with ocular discharge with or without tearing and reddened eye
fosters the resolution of the ocular discharge and reduces the need
for topical antibiotic therapy.
METHODS
Study Design
We conducted a randomized double-blind placebo-controlled
trial between May 2011 and December 2016 at the Department
of Neonatology at the Children’s University Hospital, Bern,
Switzerland. The study was approved by the Ethics Commission
of the Canton of Bern, Switzerland (215/08) and written
informed consent was obtained from parents or legal guardians
of each neonate before any procedures were conducted. The
trial was registered at the US National Institutes of Health
(ClinicalTrials.gov) NCT04122300 and at the portal for human
research in Switzerland SNCTP000003490.
Study Population
Eligible patients were preterm neonates (with a gestational age
of 24 to 37 weeks) diagnosed with white, yellow, or green
ocular discharge with or without tearing and reddened eye. The
criteria for exclusion were congenital abnormalities of the eye,
severe asphyxia, sepsis, or intracranial bleeding (intraventricular
hemorrhage ≥ grade III).
Study Interventions
Randomization and Blinding
Infants were randomly assigned (1:1) to receive either Euphrasia
or placebo. We used a randomization program (DatInf RandList
version 1.0) to generate the randomization lists. Euphrasia or
placebo was administrated at a dose of one drop in each eye four
times a day over a period of 96 h.
Study investigators, research coordinators, attending care
teams and the infants’ legual guardian were blinded to treatment
allocation. The hospital pharmacy provided the blinded study
medication: 0.2ml of Euphrasia eye drops (Weleda AG,
Arlesheim) or 0.2ml of placebo (sodium chloride 0.9%, Bichsel).
The Euphrasia eye drops and placebo were filled in neutral
Frontiers in Pediatrics | www.frontiersin.org 2 August 2020 | Volume 8 | Article 449
Meier-Girard et al. Euphrasia Drops in Preterm Neonates
tuberculin syringes of 1ml under aseptic conditions according to
the Good Manufacturing Practices (20101).
Treatment Regimen and Microbial Evaluation
At inclusion, before the start of the therapy, a bacterial/viral and
chlamydial conjunctival swab was conducted. Afterwards, both
eyes of neonates were washed four times a day (i.e., every 6 h)
with NaCl 0.9%. Subsequently, a drop of Euphrasia or placebo
was placed into the lower conjunctival sac of each eye, and
followed by a lacrimal sac digital massage. In case of worsening
of symptoms or a positive swab without any improvement
of symptoms an antibiotic therapy was initiated: bacitracin,
neomycin, polymyxin B (Neosporin ointment, HeliDerm) or
tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Schweiz
AG) after the Neosporin withdrawal in September 2013. An
additional swab was performed at 96 h (i.e., at the end of
the study).
Study Outcomes
The primary outcome was the treatment success, defined as no
ocular discharge at 96 h and no use of topical antibiotic therapy
during the 96-h intervention period. If a neonate presented a
bilateral affection, the therapy was defined as successful only if
ocular discharge had disappeared in both eyes at 96 h.
As secondary outcomes, the type of ocular discharge (white,
yellow, or green) and the presence of tearing or reddening were
recorded at baseline, and at 24, 72, and 96 h, as was the use of
topical antibiotic therapy during the 96-h intervention period.
Sample Size and Statistical Analysis
We calculated that a total of 84 infants would be needed to detect
a difference between groups, with a two-tailed α of 0.05 and a
power of 80%, for a comparison of two independent proportions
if there was an absolute increase of 30% in the primary outcome
measure (treatment success). Our initial estimate of sample size
calculation included an assumption of treatment success rate of
30% in the placebo arm. Assumptions were based on the results
of our pilot study and communication with clinicians (12).
Our primary analysis was conducted applying an intention-
to-treat approach, and therefore included all randomized infants.
Baseline characteristics of patients in the two treatment groups
were reported using frequency distribution and descriptive
statistics. Baseline characteristics included demographic
characteristics of neonates (i.e., gender, age, and weight), birth
characteristics of neonates, and age of mother at birth. Birth
characteristics included gestational age at birth (<28 weeks of
gestation (WG) was defined as extremely preterm, 28 to 32 WG
as very preterm, and 32 to 37 WG as moderate to late preterm,
in accordance with the WHO definitions), birthweight and birth
procedure (spontaneous birth, instrumental vaginal delivery, or
cesarean section).
The principal analysis of our primary outcome was an
unadjusted chi-square test comparing the proportion of events
in each treatment group.
1(2010). “EudraLex - The rules governing medicinal products in the
european union.”
A per-protocol analysis of infants who filled all inclusion
criteria was also conducted to examine the robustness of our
primary estimates.
All analyses were conducted with R, Version 3.5.1 (16).
RESULTS
Study Population
A total of 114 neonates were screened for eligibility and 84
were randomized between May 2011 and December 2016 into
the Euphrasia arm (n = 42) and the placebo arm (n = 42)
(Figure 1). Three neonates were randomized though they did not
fill the inclusion criteria (one neonate was born at full-term and
two neonates did not present any ocular discharge at inclusion).
These three neonates were allocated to the Euphrasia arm. All
randomized infants completed the trial with the exception of
three infants who were discharged before the end of the study.
The primary outcome was consequently missing for these three
infants. In total, 48 (60%) were boys, the mean postnatal age
was 21 ± 16 days, 42 (52.5%) were moderate to late preterm,
24 (30.0%) were very preterm, and 14 (17.5%) were extremely
preterm. Baseline demographic and clinical characteristics were
similar in both treatment arms (Table 1).
Ocular Health at Baseline
Laterality of the ocular discharge (i.e., unilateral or bilateral) was
similar in both treatment arms (Table 2). In the Euphrasia arm,
10 (25.0%) neonates presented a bilateral ocular discharge at
baseline, resulting in 50 eyes with ocular discharge among the
42 neonates (59.5%). In the placebo arm, 17 (40.5%) neonates
presented a bilateral ocular discharge, resulting in 59 eyes with
ocular discharge among the 42 neonates (70.2%).
Symptoms at baseline were similar in both treatment arms
with the exception of the reddening (Table 3). In both treatment
arms, neonates presented mainly with yellow ocular discharge,
and slight tearing. More neonates presented with green ocular
discharge in the Euphrasia arm. In the Euphrasia arm, ocular
discharge was accompanied by reddening in more eyes than in
the placebo arm. The reddening was bilateral for 5 neonates in
the Euphrasia arm, while this was the case for only one neonate
in the placebo arm.
Therapy Outcome
Primary Outcome
A total of 43 (53.1%) infants met our primary outcome of
treatment success. Treatment success did not significantly differ
between treatment arms [22 (55.0%) in the Euphrasia arm vs. 21
(51.2%) in the placebo arm, p= 0.85] (Table 4).
Topical Antibiotic Therapy
The use of topical antibiotic therapy was similar in both
treatment arms (Table 4). Within the 96-h intervention period, 8
(19.0%) neonates in the Euphrasia arm and 8 (19.0%) neonates
in the placebo arm received a topical antibiotic therapy (p =
0.99). The time to initiation of the antibiotic therapy did not
significantly differ between treatment arms and symptoms were
observed to decrease similarly in both groups after introduction
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FIGURE 1 | Participant flow.
of topical antibiotic therapy. Neonates who received topical
antibiotic therapy presented at inclusion significantly more
tearing as compared to neonates who did not receive topical
antibiotic therapy [21 (87.5%) eyes with tearing vs. 49 (58.3%)
eyes with tearing, respectively, p= 0.008] (Table E1).
Among the 16 neonates who received a topical antibiotic
therapy, results of swabs performed at inclusion were similar in
both groups (Table E2). Swabs were positive for Staphylococcus
aureus (S. aureus) in 9 neonates. Swabs were negative at inclusion
in three neonates. Due to a substantial worsening of symptoms
in these three neonates, it had not been possible to wait for the
results of the swabs before initiating the antibiotic therapy.
Among the 68 (81.0%) neonates who did not receive any
topical antibiotic therapy, results of swabs performed at inclusion
were similar in both groups (Table E2). Swabs were positive in
31 (45.6%) neonates [16 (47.1%) in the Euphrasia arm vs. 15
(44.1%) in the placebo arm, p = 0.81]. The swabs were mainly
positive to S. aureus [16/31 (51.2%) swabs]. At 96 h, 21 (70.0%)
of the neonates with a positive swab at inclusion and 22 (61.1%)
of the neonates with a negative swab at inclusion were free of
ocular discharge (p = 0.45) (Table E3). Therefore, no significant
difference in the success of treatment at 96 h was observed based
on the presence of microbiological agents at the beginning of
the affection. No significant difference was observed between
treatment arms (Table E3).
None of the neonates tested positive for Neisseria gonorrhoeae
and C. trachomatis.
Resolution of Ocular Discharge and Evolution of
Other Symptoms
Among the 68 (81.0%) neonates who did not receive any topical
antibiotic therapy, in the Euphrasia arm, 7 (21.9%) neonates
presented a bilateral ocular discharge at baseline, resulting in
39 eyes with ocular discharge among 34 neonates (57.4%)
(Table 2). In the placebo arm, 12 (35.3%) neonates presented
a bilateral ocular discharge, resulting in 46 eyes with ocular
discharge among the 34 neonates (67.6%). Table 5 provides an
overview according to treatment arm of how symptoms (i.e.,
ocular discharge, reddening, tearing) evolved in neonates who
did not receive any topical antibiotic therapy over the 96 h
of intervention.
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TABLE 1 | Baseline characteristics (n = 84 neonates).
Euphrasia (n = 42 neonates) Missing data Placebo (n = 42 neonates) Missing data
Demographic characteristics
Sex, male 27 (64.3%) - 24 (57.1%) -
Postnatal age, days 12 [10–22] - 17 [12–27] -
Weight, g 1807 ± 523 1 1722 ± 443 -
Birth characteristics
Gestational age at birth, week of gestationa - -
Extremely preterm <28 7 (16.7%) 8 (19.0%)
Very preterm [28;31(6/7)] 13 (31.0%) 12 (28.6%)
Moderate to late preterm [32;36(6/7)] 21 (50.0%) 22 (52.4%)
Full-term ≥37b 1 (2.4%) 0 (0.0%)
Birthweight, g 1,608 [1,226–1,834] 1,498 [988–1,699] -
Age of mother at delivery, years 35.0 [30.2–37.0] - 32.5 [29.0–36.7] -
Birth procedure - 2
Spontaneous birth 10 (23.8%) 5 (12.5%)
Instrumental vaginal delivery 2 (4.8%) 3 (7.5%)
Cesarean section 30 (71.4%) 32 (80.0%)
Data are expressed as mean ± standard deviation, median [interquartile range], and number (percentage).
a In accordance with the WHO definitions.
bOne neonate was randomized though he was born at full-term.
TABLE 2 | Laterality of ocular discharge at baseline according to treatment arm.
All neonates (n = 84 neonates) No topical antibiotic therapy (n = 68 neonates)
Euphrasia
(n = 42 neonates)
Placebo
(n = 42 neonates)
MD Euphrasia
(n = 34 neonates)
Placebo
(n = 34 neonates)
MD
At least one eye with ocular discharge 40 (95.2%)a 42 (100.0%) - 32 (94.1%)a 34 (100.0%) -
Laterality of ocular discharge - -
One eye 30 (75.0%) 25 (59.5%) 25 (78.1%) 22 (64.7%)
Both eyes 10 (25.0%) 17 (40.5%) 7 (21.9%) 12 (35.3%)
Data are expressed as number (percentage).
aTwo neonates were randomized though they did not present with ocular discharge at baseline.
• Resolution of ocular discharge was observed in 34 (89.5%) eyes
in the Euphrasia arm and in 39 (86.7%) in the placebo arm
(p = 0.83). Time to resolution of ocular discharge did not
differ between arms (p = 0.16). Relapse of ocular discharge
was significantly higher in the Euphrasia arm as compared
to the placebo arm [13 (38.2%) eyes vs. 6 (15.8%) eyes, p =
0.03]. Resolution at 96 h was similar in both treatment arms
[ocular discharge in 12 (30.8%) eyes in the Euphrasia arm vs.
12 (27.7%) eyes in the placebo arm, p= 0.73].
• Resolution of reddening was observed in 26 (96.3%) eyes in
the Euphrasia arm and in 15 (100.0%) eyes in the placebo arm
(p = 0.99). In the Euphrasia arm, time to resolution tended to
be shorter [24 (92.3%) vs. 12 (80.0%) in the placebo arm, p =
0.34] and relapse or first signs of reddening during the 96-h
intervention tended to be lower [3 (7.9%) eyes vs. 8 (18.2%)
eyes in the placebo arm, p = 0.17]. Reddening at 96 h was
similar in both treatment arms [reddening in 1 (2.6%) eyes
in the Euphrasia arm vs. 2 (4.5%) eyes in the placebo arm,
p= 0.99].
• Resolution of tearing was observed in 23 (100.0%) eyes
in the Euphrasia arm and in 24 (96.0%) eyes in the
placebo arm (p = 0.99). Time to resolution did not
differ between arms (p = 0.99). Relapse of first signs
of tearing during the 96-h intervention was similar in
both treatment arms (p = 0.73). Tearing at 96 h tended
to be lower in the Euphrasia arm [5 (12.8%) eyes in
the Euphrasia arm vs. 12 (27.3%) eyes in the placebo
arm, p= 0.10].
Sensitivity Analyses
A per-protocol analysis of infants who met all inclusion criteria
did not alter the conclusions on the primary (treatment success
was 19 (52.8%) in the Euphrasia arm vs. 21 (51.2%), p = 0.89)
and secondary outcomes (results not shown).
The analysis of the treatment success according to treatment
arm and preterm status (extremely and very preterm vs. moderate
to late preterm and full-term) did not show any significant
difference (results not shown).
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TABLE 3 | Ocular health at baseline according to treatment arm (n = 84
neonates, 111 affected eyes).
Euphrasia
(n = 52 eyes)
Missing
data
Placebo
(n = 59 eyes)
Missing
data
Symptoms at baseline
Ocular discharge 50 (96.2%)a - 59 (100%) -
Type of ocular discharge 1 -
White 5 (10.2%) 8 (13.6%)
Yellow 40 (81.6%) 50 (84.7%)
Green 4 (8.2%) 1 (1.7%)
Reddening 33 (63.5%) - 21 (36.2%) 1
Tearing 34 (66.6%) 1 36 (63.2%) 2
Data are expressed as number (percentage).
aTwo neonates were randomized though they did not present with ocular discharge
at baseline.
DISCUSSION
Main Results
In this study with 84 preterm neonates with ocular discharge
treated with either Euphrasia eye drops or placebo, Euphrasia did
not significantly improve treatment success as compared to the
placebo arm, defined as no ocular discharge at 96 h and no use of
topical antibiotic therapy during the 96-h intervention.
However, this study shows a remarkably high treatment
success rate at 96 h [i.e., no ocular discharge at 96 h and no
use of topical antibiotic therapy: n = 43 (53.1%)] and a low
rate of topical antibiotic use [n = 16 (19.0%)]. At the time of
the study, treatment success was expected in 3 to 5 days, with
50 to 80% of neonates receiving a topical antibiotic therapy.
Treatment success and use of topical antibiotic therapy were
similar in both treatment arms. We explain these results by
the systematic eye washing and lacrimal sac massage, newly
introduced in the Department of Neonatology at the University
Children’s Hospital, Bern, Switzerland, as part of this study. The
massage of the lacrimal sac has been recognized as a very efficient
therapy (17), and is recommended as the first-line treatment in
CNLDO (18, 19).
We observed a high rate of treatment success at 96 h in
neonates with a positive bacteriological swab at inclusion who did
not go on to receive a topical antibiotic therapy. No relationship
was observed between the microbiological agent identified and
the success of treatment. These results support that topical
antibiotics should not be used systematically as the first-line
treatment of preterm neonates presenting with ocular discharge.
Rather, the first-line treatment of lacrimal sac massage should be
applied first.
In the Euphrasia arm, a trend was observed for shorter time to
reddening resolution as well as lower rate of relapse, suggesting
that Euphrasia might be of benefit against reddening. However,
the difference was not statistically significant, possibly due to a
lack of power.
The rate of relapse of ocular discharge in the subgroup of
neonates who did not go on to receive a topical antibiotic
therapy was significantly higher in the Euphrasia arm. Some of
the relapses in the Euphrasia arm were observed in neonates
initially presenting a green ocular discharge, indicating a more
severe affection, while no green ocular discharge was observed in
the placebo arm. Moreover, in this subgroup, significantly more
infants presented with a reddening at baseline in the Euphrasia
arm, also indicating a potentially more severe affection. At 96 h,
the ocular discharge relapses had resolved in the Euphrasia
arm such that there was no significant difference between
treatment arms.
Finally, the pattern of tearing fluctuated during the
intervention period with high rates of resolution and relapse.
This is to be expected given the nature of the mechanical
mechanism underlying this symptom. At the end of the
intervention, we observed a trend for less tearing in the
Euphrasia arm.
Strengths and Weaknesses of the Study
To the best of our knowledge, this is the first double-blind
randomized controlled trial comparing Euphrasia eye drops to
placebo in the first-line treatment of ocular discharge. Also, this
trial investigated preterm neonates, a vulnerable population that
is highly under-represented in clinical trials.
A limitation of the study is the absence of grading of the
symptoms (i.e., ocular discharge, tearing, and reddening). We
limited our analysis to the presence or absence of symptoms
to avoid any subjectivity in the assessment of the symptoms.
A second limitation is the small sample size with respect
to the assessment of the secondary endpoints (e.g., tearing
and reddening) which may have prevented some reasonably
strong associations from coming up as significant. A third
limitation is the non-independence of eyes in neonates with a
bilateral affection.
Generalizability of the Trial Findings
Clinical characteristics observed in the present study were
consistent with those reported in prior studies. Laterality
of symptoms occurred in approximately one-third of cases,
consistent with prior reports (20–23). Ocular discharge was
accompanied by tearing in 63% of neonates at baseline. Tearing
is described also in ∼80–90% of patients with CNLDO but is
not systematically present in preterm neonates because the tear
production is not fully developed (20, 22–25). In general, ocular
discharge can also be a first sign of CNLDO, which cannot
definitively be ruled out at first stage of illness.
We found a success rate at 96 h of 53.1% which is in
accordance with Stolovitch et al. who showed a success rate
(defined as no epiphora or discharge) of 56% after the first
attempt of lacrimal sacmassage in children aged< 2months with
CNLDO (26).
None of the neonates tested positive for Neisseria gonorrhoeae
or C. trachomatis. This supports the efficacy of the preventive
measures applied in Switzerland. No association was observed
between the microbiological flora and the success of therapy.
This underlines the different possible evolutions for the same
pathogen and thus supports the use of conservative management
as a first-line treatment. Furthermore, as preterm neonates have a
premature immune system, the use of antibiotic therapy in these
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TABLE 4 | Treatment success at 96 h (primary outcome) and use of topical antibiotic therapy according to treatment arm (n =8 4 neonates).
Euphrasia (n = 42 neonates) Missing data Placebo (n = 42 neonates) Missing data p-valuea
Success of treatment at 96 h 22 (55.0%) 2 21 (51.2%) 1 0.85
Topical antibiotic therapy 8 (19.0%) - 8 (19.0%) - 0.99
Time to initiation of antibiotic therapyb - - 0.99
Within 48 h 5 (62.5%) 4 (50.0%)
Between 48 and 96 h 3 (37.5%) 4 (50.0%)
Decreasing of symptoms after topical antibiotic therapy 6 (75.0%) - 6 (75.0%) - 0.99
Data are expressed as number (percentage).
Treatment success was defined as no ocular discharge at 96 h and no use of topical antibiotic therapy during the 96-h intervention period. If a neonate presented a bilateral affection,
the treatment was defined as successful only if ocular discharge had disappeared in both eyes at 96 h.
aChi-square test or Fischer test, as appropriate.
b In the 8 neonates who received a topical antibiotic therapy.
TABLE 5 | Evolution of symptoms in neonates who did not go on to receive a topical antibiotic therapy according to treatment arm (n = 68 neonates, 87 affected eyes).
Euphrasia (n = 41 eyes) Missing data Placebo (n = 46 eyes) Missing data p-valuea
Ocular discharge
Ocular discharge at baseline 39 (95.1%)b - 46 (100.0%) - 0.99
Resolution during intervention 34 (89.5%) 1 39 (86.7%) 1 0.83
Time to resolution - - 0.16
24–48 h 22 (64.7%) 31 (79.5%)
72–96 h 12 (35.3%) 8 (20.5%)
Relapse during intervention 13 (38.2%) 1 6 (15.8%) 1 0.03
Ocular discharge at 96 h 12 (30.8%) 2 12 (27.7%) 2 0.73
Reddening
Reddening at baseline 27 (65.9%) - 15 (33.3%) 1 0.003
Resolution during intervention 26 (96.3%) - 15 (100.0%) - 0.99
Time to resolution - - 0.34
24–48 h 24 (92.3%) 12 (80.0%)
72–96 h 2 (7.7%) 3 (20.0%)
Relapse or first signs during intervention 3 (7.9%) 3 8 (18.2%) 2 0.17
Reddening at 96 h 1 (2.6%) 2 2 (4.5%) 2 0.99
Tearing
Tearing at baseline 24 (60.0%) 1 25 (56.8%) 2 0.77
Resolution during intervention 23 (100.0%) 1 24 (96.0%) - 0.99
Time to resolution - - 0.99
24–48 h 19 (82.6%) 19 (79.2%)
72–96 h 4 (17.4%) 5 (20.8%)
Relapse or first signs during intervention 18 (46.2%) 2 22 (50.0%) 2 0.73
Tearing at 96 h 5 (12.8%) 2 12 (27.3%) 2 0.10
Data are expressed as number (percentage).
aChi-square test or Fischer test, as appropriate.
bTwo neonates did not fill the inclusion criteria (intention-to-treat approach).
individuals might facilitate the overgrowth of resistant bacteria in
the nasolacrimal system (22).
We observed a trend for a shorter time to reddening resolution
and less relapse of reddening with Euphrasia, as well as a trend
for less tearing at 96 h. This is in the line with previous studies
showing promising results regarding the use of Euphrasia in
the symptomatic treatment of conjunctivitis of any etiology (i.e.,
reddening, burning, and veiling of vision) (13).
Conclusions and Implications
In this study, Euphrasia did not improve ocular discharge at
96 h and did not decrease the use of topical antibiotic therapy.
However, this study provides evidence of the clinical efficacy
of conservative therapy (i.e., lacrimal sac massage) as a first-
line treatment in preterm neonates with ocular discharge. No
relationship between the microbiological agent identified and the
success of treatment was observed. These results support that
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topical antibiotics should not be used systematically as the first-
line treatment of ocular discharge, including in preterm neonates.
Finally, results suggest that Euphrasia may be of benefit for
symptoms such as reddening and tearing, and thus improve the
comfort of patients.
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